Study S001212

The Effect of LY2189265 on Insulin Secretion in Response to Intravenous Glucose Infusion

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01300260
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: TRIPLE
Status: COMPLETED
Enrollment: 32
Start: 2011-02
Primary completion: 2011-08
Lead sponsor: Eli Lilly and Company
Conditions: Diabetes Mellitus, Type 2
Interventions: BIOLOGICAL:LY2189265; DRUG:Placebo; DRUG:Insulin; DRUG:Glucose; DRUG:Glucagon
Results posted: TRUE
Secondary identifiers: OTHER:H9X-MC-GBCI

Registered primary outcomes

Maximum Insulin Concentration (Cmax) - First Phase Response [0-10 minutes after dextrose bolus on Day 3 postdose]
Area Under the Insulin Concentration-time Curve (AUC) - First Phase Response [0-10 minutes after dextrose bolus on Day 3 postdose]
Maximum Insulin Concentration (Cmax) - Second Phase Response [10-180 minutes after dextrose bolus on Day 3 postdose]
Insulin Area Under the Curve (AUC) - Second Phase Response [10-180 minutes after dextrose bolus on Day 3 post dose]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.